Declining ad rates close two CMPMedica titles

Share this article:
Declining ad rates close two CMPMedica titles
Declining ad rates close two CMPMedica titles
CMPMedica ceased to publish two of its titles – Infections in Medicine and AIDS Reader – due to a continuing decline in print advertising sales.

Early last week, the company announced “company-wide” layoffs that “touched every department,” according to Amy Erdman, CMPMedica's director of marketing, research and circulation. Erdman declined to put a number on the layoffs. An article in Folio put the number of layoffs at “nearly 30,” citing a source familiar with the cuts.

Despite the absence of print issues, both titles will continue to “maintain a digital presence,” said Erdman, adding that other areas of the business, including digital advertising, are seeing positive growth. Erdman said the company does not have any current plans to stop print publication of other CMPMedica titles, which include Psychiatric Times, The Journal of Respiratory Diseases, Physicians Practice, Oncology News International, and others.

CMPMedica is a division of United Business Media, which also owns PR Newswire, TechWeb, and other information trade services and distribution channels.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...